Triple Negative Breast Cancer (TNBC) is a very aggressive type of breast cancer which affects upwards of 1 million women worldwide. Though strides are being made in the development of better screening tools for diseases like cancer, many are not robust enough to distinguish between various subtypes of cancer. The need for this technology is imperative in cases such as TNBC, where the disease is aggressive, has a high rate of metastasis, and relapse is more common compared to other non metastatic cancers. Within the last decade, Raman spectroscopy has become a promising tool of investigation for many research groups in filling this need. This project supports the clinical adoption of this tool by developing a framework to distinguish subtypes of breast cells based on metabolic data acquired via Raman spectroscopy. More specifically, this project explores several biologically relevant Raman spectroscopy ratios.